Non-cystic fibrosis Bronchiectasis

August 3, 2017August 3, 2017

Aradigm Asks FDA for New Drug Application for Linhaliq to Treat Bacterial Infection in NCFBE

News

Aradigm is asking the U.S. Food and Drug Administration (FDA) for permission to market its candidate therapy, Linhaliq, to treat non-cystic fibrosis bronchiectasis (NCFBE) with chronic lung infections caused by Pseudomonas aeruginosa. ... Read more

December 6, 2016December 6, 2016

Positive Trial Results of Pulmaquin Reported for Non-CF Bronchiectasis Patients with Chronic Lung Infections

Bronchiectasis, News

Aradigm reported positive results from the ORBIT-3 (NCT01515007 ) and ORBIT-4 (NCT02104245) Phase 3 clinical trials assessing Pulmaquin for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE) in patients with chronic lung infection by Pseudomonas aeruginosa bacteria. The pivotal clinical trials ... Read more

October 20, 2016October 20, 2016

#CHEST2016 – Bayer to Present New Data on PAH and Bronchiectasis Therapies

Bronchiectasis, News, Pulmonary Hypertension

Bayer announced it will be giving three oral presentations on lead investigative therapies Adempas (riociguat) for the treatment of pulmonary arterial hypertension (PAH), and ciprofloxacin DPI (dry powder for inhalation) to treat non-cystic ... Read more

May 16, 2016May 16, 2016

Aradigm’s Candidates for NCFBE Featured at ATS 2016

Bronchiectasis, Cystic Fibrosis, News

The American Thoracic Society (ATS) is hosting the ATS 2016 International Conference through May 18 in San Francisco, Calif. Aradigm, an emerging pharmaceutical focused on drugs for the prevention and ... Read more

October 13, 2015November 6, 2015

Aradigm Announces Completion of Patient Enrollment for Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis

Bronchiectasis, News

Aradigm Corporation, a pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases, recently announced the conclusion of patient enrollment in the ... Read more

May 1, 2015November 6, 2015

Two Non-Cystic Fibrosis Bronchiectasis Scoring Systems Shown to Agree in Predicting Disease Severity

Bronchiectasis, News

Categorizing patients with non-cystic fibrosis bronchiectasis (NCFB) according to disease similarities is beneficial to drawing connections between symptoms, treatments, and prognoses. Recognizing this need, scientists have developed two scoring systems: ... Read more

March 3, 2015November 6, 2015

Non-Cystic Fibrosis Bronchiectasis Patients Affected Most by Pseudomonas Aeruginosa

Bronchiectasis, News

Researchers at the University of Milano-Bicocca in Italy published in the International Journal of Mycobacteriology their findings regarding the clinical outcome of patients with non-cystic fibrosis bronchiectasis with chronic lung infection ... Read more

January 16, 2015November 6, 2015

Ciprofloxacin Dry Powder for Inhalation Tested in Bronchiectasis

Bronchiectasis, News

Bayer and Novartis, two leading pharmaceutical companies, are developing ciprofloxacin dry powder for inhalation (DPI, brand name Cipro Inhale) to treat non-cystic fibrosis bronchiectasis. A phase 2 clinical trial, “Evaluation ... Read more

January 16, 2015November 6, 2015

Aradigm’s Non-Cystic Fibrosis Bronchiectasis Drug Pulmaquin Granted New Patents in Europe and Australia

Bronchiectasis, News

Aradigm Corporation has announced that it recently obtained two new patents providing coverage for formulations of liposomal and free ciprofloxacin in Europe (E.U. Patent No. 2079443) and Australia (AU2012211514). Both patents cover ... Read more

December 2, 2014November 6, 2015

Bayer’s Non-cystic Fibrosis Bronchiectasis, Pneumonia Drugs Gain QIDP Status From FDA

Bronchiectasis, News

Recently, two Bayer experimental drugs, Amikacin Inhale and Ciprofloxacin Dry Powder for Inhalation (DPI), were granted the title of qualified infectious disease products (QIDP) by the U.S. Food and Drug Administration ... Read more